Literature DB >> 11035394

Current perspectives on intracavernosal pharmacotherapy for erectile dysfunction.

H Porst1.   

Abstract

Thirty percent of males afflicted with erectile dysfunction (ED) do not respond to oral drugs, another 15% reveal contraindications to currently available therapy, and a subset of patients actually prefer injection therapy due to its predictable short time-to-onset of erection and reliable rigidity compared to oral drugs. This paper provides both a historical and current perspective on intracavernosal therapy and reviews the popular injectable therapeutic agents that are currently used for the treatment of ED. Emphasis is placed on the efficacy, mechanism of action and side effect profiles of approved and experimental injectable pharmacotherapy for ED. International Journal of Impotence Research (2000) 12, Suppl 4, S91-S100.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11035394     DOI: 10.1038/sj.ijir.3900585

Source DB:  PubMed          Journal:  Int J Impot Res        ISSN: 0955-9930            Impact factor:   2.896


  3 in total

1.  Delivery of intracavernosal therapies using needle-free injection devices.

Authors:  D O'Kane; L Gibson; J du Plessis; A Davidson; D Bolton; N Lawrentschuk
Journal:  Int J Impot Res       Date:  2017-07-27       Impact factor: 2.896

2.  The real-life safety and efficacy of vardenafil: an international post-marketing surveillance study of 2824 patients from the Middle East.

Authors:  A Kamel; R Khaouli; M Sabha; K Al Mitwally; W Fouad; H Landen
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

Review 3.  Intracavernous pharmacotherapy for erectile dysfunction.

Authors:  Anthony J Bella; Gerald B Brock
Journal:  Endocrine       Date:  2004 Mar-Apr       Impact factor: 3.925

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.